Mark L. Baum
2014
In 2014, Mark L. Baum earned a total compensation of $634K as Chief Executive Officer at Imprimis Pharmaceuticals, a 88% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $203,980 |
|---|---|
| Option Awards | $94,718 |
| Salary | $327,456 |
| Other | $7,800 |
| Total | $633,954 |
Baum received $327.5K in salary, accounting for 52% of the total pay in 2014.
Baum also received $204K in non-equity incentive plan, $94.7K in option awards and $7.8K in other compensation.
Rankings
In 2014, Mark L. Baum's compensation ranked 9,459th out of 13,032 executives tracked by ExecPay. In other words, Baum earned more than 27.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,459 out of 13,032 | 27th |
Division Manufacturing | 3,567 out of 4,965 | 28th |
Major group Chemicals And Allied Products | 1,218 out of 1,690 | 28th |
Industry group Drugs | 964 out of 1,369 | 30th |
Industry Pharmaceutical Preparations | 737 out of 1,042 | 29th |
Source: SEC filing on April 10, 2015.
Baum's colleagues
We found one more compensation record of an executive who worked with Mark L. Baum at Imprimis Pharmaceuticals in 2014.
2014
Andrew Boll
Imprimis Pharmaceuticals
Chief Financial Officer
News
Imprimis Pharmaceuticals CEO Mark Baum's 2022 pay falls 84% to $1.2M
April 28, 2023
Imprimis Pharmaceuticals CEO Mark Baum's 2021 pay jumps 195% to $7.3M
April 26, 2022
Imprimis Pharmaceuticals CEO Mark Baum's 2020 pay jumps 80% to $2.5M
April 23, 2021
Imprimis Pharmaceuticals CEO Mark Baum's 2019 pay jumps 30% to $1.4M
April 24, 2020
Imprimis Pharmaceuticals CEO Mark Baum's 2018 pay rises 16% to $1.1M
April 25, 2019